Cardiovascular Disease (CVD)

Serious Cardiovascular Events Linked to Low BMD in the CKD Population

Publish Date August 3, 2021

Lowest vs highest tertile of total hip BMD was significantly associated with a 2.2-fold increased risk for major adverse cardiovascular events, study finds.

Risk for Atherosclerotic CVD Increased With South Asian Ancestry

Publish Date August 2, 2021

Higher risk persisted after adjustment for broad range of clinical, anthropometric, and lifestyle risk factors

Rates of Adverse Events Lower With Apixaban for A-Fib in Older Adults

Publish Date July 30, 2021

Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels

Orlistat Therapy for Obesity Linked to Fewer Major Adverse Cardiovascular Events

Publish Date July 29, 2021

A team of UK-based investigators explored the long-term cardiovascular outcomes in patients with obesity who were administered orlistat therapy.

Hyperuricemia Increases Risks for Cardiovascular, All-Cause Mortality

Publish Date July 27, 2021

Each 1 mg/dL rise in uric acid level was significantly associated with a 21% and 10% increased risk for cardiovascular and all-cause mortality, respectively, a study found.

Review: Benefit Outweighs Harm of Statins for Primary Prevention of CVD

Publish Date July 26, 2021

Risk for adverse events attributable to statins low when used for primary prevention of cardiovascular disease

Catheter Ablation Improves A-Fib Outcomes in Racial/Ethnic Minorities

Publish Date July 26, 2021

In contrast, much higher event rate seen for racial and ethnic minorities randomly assigned to drug therapy in CABANA trial

FDA Requests Removal of Pregnancy Contraindication for Statins

Publish Date July 23, 2021

The FDA conducted a comprehensive review of all available data associated with the use of statins during pregnancy.

Dapagliflozin Safe, Effective in Advanced Chronic Kidney Disease

Publish Date July 22, 2021

Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.

Anemia, SHPT Are Possible Cardiovascular Risk Factors in Kidney Transplant Recipients

Publish Date July 22, 2021

In a small study, approximately a third of kidney transplant recipients had anemia and half had persistent secondary hyperparathyroidism.